Kymera Therapeutics, Inc.
KYMR
Classifica tra le azioni
#2182
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Prezzo delle azioni
$114.06
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$9.38B
Variazione (1 giorno)
5.54%
Variazione (1 anno)
95.57%
Paese
US
Scambia Kymera Therapeutics, Inc. (KYMR)
Categoria
Healthcare
Ricavi di Kymera Therapeutics, Inc. (KYMR)
Ricavi nel Jun 2026 TTM: $104.99M
Secondo gli ultimi rapporti finanziari di Kymera Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $104.99M. Nel 2023, l'azienda ha registrato ricavi di $78.59M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $46.83M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Kymera Therapeutics, Inc. da 2018 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 5,635.16% |
NL
|
